SG11201903091VA - Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors - Google Patents

Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Info

Publication number
SG11201903091VA
SG11201903091VA SG11201903091VA SG11201903091VA SG11201903091VA SG 11201903091V A SG11201903091V A SG 11201903091VA SG 11201903091V A SG11201903091V A SG 11201903091VA SG 11201903091V A SG11201903091V A SG 11201903091VA SG 11201903091V A SG11201903091V A SG 11201903091VA
Authority
SG
Singapore
Prior art keywords
kangning
dcb
lane
international
taipei city
Prior art date
Application number
SG11201903091VA
Inventor
Shao-Zheng Peng
Chu-Bin Liao
Hung-Kai Chen
Chen-Hsuan Ho
Hung-Jyun Huang
Shian-Yi Chiou
Original Assignee
Dev Ct Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dev Ct Biotechnology filed Critical Dev Ct Biotechnology
Publication of SG11201903091VA publication Critical patent/SG11201903091VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111 011100111111110111110111101111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/071348 Al 19 April 2018 (19.04.2018) WIP0 1 PCT (51) International Patent Classification: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, C07D 241/40 (2006.01) C07D 401/12 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07D 241/44 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/US2017/055809 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 09 October 2017 (09.10.2017) Published: (25) Filing Language: — English with international search report (Art. 21(3)) (26) Publication Language: English (30) Priority Data: 62/406,328 10 October 2016 (10.10.2016) US (71) Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY; No. 101, Lane 169, Kangning St , New Taipei City, 221 (TW). DCB-USA LLC [US/US]; 1007 N. Orange Street, Wilmington, DE 19801 (US). (72) Inventors: PENG, Shao-Zheng; c/o DCB, No. 101, Lane _ 169, Kangning St., New Taipei City, 221 (TW). LIAO, _ Chu-bin; c/o DCB, No. 101, Lane 169, Kangning St New , Taipei City, 221 (TW). CHEN, Hung-Kai; c/o DCB, No. = 101, Lane 169, Kangning St., New Taipei City, 221 (TW). HO, Chen-Hsuan; c/o DCB, No. 101, Lane 169, Kangning = St., New Taipei City, 221 (TW). HUANG, Hung-Jyun; c/ o DCB, No. 101, Lane 169, Kangning St., New Taipei City, 221 (TW). CHIOU, Shian-Yi; c/o DCB, No. 101, Lane — = 169, Kangning St., New Taipei City, 221 (TW). (74) Agent: LIANG, T., Chyau; Liang Legal Group, PLLC, 6020 Annapolis Street, Houston, TX 77005 (US). — — Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = (81) = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = — SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — 1-1 GC (54) Title: QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 71' M (57) : A compound, capable of inhibiting kinases, for the treat- 1-1 R 2 ments of diseases or disorders mediated by such kinases, has a structure IN R 1 X R14] of formula (I) or a stereoisomer, a tautomer, a pharmaceutically accept- = --.... (I) able salt thereof. The compound can be used in the treatments of diseases 1 0 1-1 N U Z G or conditions mediated by CSF-IR, c-KIT, FLT3, or PDGFR kinases. = ei Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases. O
SG11201903091VA 2016-10-10 2017-10-09 Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors SG11201903091VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662406328P 2016-10-10 2016-10-10
PCT/US2017/055809 WO2018071348A1 (en) 2016-10-10 2017-10-09 Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201903091VA true SG11201903091VA (en) 2019-05-30

Family

ID=61905910

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903091VA SG11201903091VA (en) 2016-10-10 2017-10-09 Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Country Status (13)

Country Link
US (1) US10689362B2 (en)
EP (1) EP3523285A4 (en)
JP (1) JP7206188B2 (en)
KR (1) KR102609813B1 (en)
CN (1) CN110325515B (en)
AU (1) AU2017342928B2 (en)
BR (1) BR112019007271A2 (en)
CA (1) CA3039919A1 (en)
IL (1) IL265829B (en)
RU (1) RU2019113764A (en)
SG (1) SG11201903091VA (en)
TW (1) TWI648266B (en)
WO (1) WO2018071348A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4214198A1 (en) * 2020-09-21 2023-07-26 Hutchison Medipharma Limited Heteroaromatic compounds and uses thereof
WO2022232116A1 (en) * 2021-04-26 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Biochemical activation of dysfunctional skeletal stem cells for skeletal regeneration
WO2023082145A1 (en) * 2021-11-11 2023-05-19 4B Technologies (Suzhou) Limited Intermediate compound of quinoxaline and preparation process thereof
CN114605391B (en) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 Quinoxaline derivative, preparation method and application thereof
CN115141177B (en) * 2022-08-30 2022-12-09 福贝生物科技(苏州)有限公司 Novel crystal form of quinoxaline compound maleate and preparation method thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017329A1 (en) * 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US7304092B1 (en) * 2002-11-12 2007-12-04 Yale University Compounds and methods for treating tumors, cancer and hyperproliferative diseases
FR2856686A1 (en) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic BENZOTHIAZOLE-4,7-DIONES AND BENZOOXAZOLE-4,7-DIONES SUBSTITUTED IN POSITION 5 OR 6 AND THEIR PREPARATION METHODS
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
LT2010528T (en) * 2006-04-19 2017-12-27 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
CN101432281B (en) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN102036963B (en) * 2008-05-23 2013-08-21 诺瓦提斯公司 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013112950A2 (en) * 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
LT2840080T (en) 2012-04-17 2018-02-12 Fujifilm Corporation Nitrogen-containing heterocyclic compound or salt thereof
EP2916838B1 (en) * 2012-11-12 2019-03-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10517844B2 (en) 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Also Published As

Publication number Publication date
CA3039919A1 (en) 2018-04-19
RU2019113764A (en) 2020-11-13
JP7206188B2 (en) 2023-01-17
KR102609813B1 (en) 2023-12-07
US20190308949A1 (en) 2019-10-10
TW201817720A (en) 2018-05-16
RU2019113764A3 (en) 2021-01-29
US10689362B2 (en) 2020-06-23
IL265829A (en) 2019-06-30
EP3523285A4 (en) 2020-04-22
KR20190059959A (en) 2019-05-31
CN110325515B (en) 2023-06-20
BR112019007271A2 (en) 2019-09-17
AU2017342928B2 (en) 2021-09-09
IL265829B (en) 2022-06-01
CN110325515A (en) 2019-10-11
EP3523285A1 (en) 2019-08-14
AU2017342928A1 (en) 2019-05-23
WO2018071348A1 (en) 2018-04-19
TWI648266B (en) 2019-01-21
JP2019530708A (en) 2019-10-24

Similar Documents

Publication Publication Date Title
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201903091VA (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903487SA (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201808582RA (en) Pyrrolotriazine compounds as tam inhibitors
SG11201909278SA (en) Fungicidal oxadiazoles
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201408791TA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201407458XA (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201804223TA (en) OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SG11201909083UA (en) Piperidines as covalent menin inhibitors